Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2127-2135

  Zheng, Fang ^a   Li, Huiyu ^a   Liang, Kaiwei ^a   Du, Yimei ^a   Guo, Dongmei ^a   Huang, Shiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chronic myeloid leukemia; HERG channel; Imatinib; VEGF

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; IMATINIB; POTASSIUM CHANNEL HERG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEK293; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; DOWN-REGULATION; ETHER-A-GO-GO POTASSIUM CHANNELS; FLOW CYTOMETRY; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PATCH-CLAMP TECHNIQUES; PIPERAZINES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872781379     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0102-y     Document Type: Article

References (34)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-56.
2. Holyoake DT. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol. 2001;113(1):11-23. doi:bjh2558.
3. Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program. 2009;461-76. doi:10.1182/asheducation-2009.1.461.
4. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97(8):2440-8.
5. Wijetunge S, Dolphin AC, Hughes AD. Tyrosine kinases act directly on the alpha1 subunit to modulate Ca(v)2.2 calcium channels. Biochem Biophys Res Commun. 2002;290(4):1246-9. doi:10.1006/bbrc.2001.6248.
6. Liu H, Sun HY, Lau CP, Li GR. Regulation of voltage-gated cardiac sodium current by epidermal growth factor receptor kinase in guinea pig ventricular myocytes. J Mol Cell Cardiol. 2007;42(4):760-8. doi:10.1016/j.yjmcc.2006.10.013.
7. Du XL, Gao Z, Lau CP, Chiu SW, Tse HF, Baumgarten CM, et al. Differential effects of tyrosine kinase inhibitors on volumesensitive chloride current in human atrial myocytes: evidence for dual regulation by Src and EGFR kinases. J Gen Physiol. 2004;123(4):427-39. doi:10.1085/jgp.200409013.
8. Gao Z, Lau CP, Wong TM, Li GR. Protein tyrosine kinasedependent modulation of voltage-dependent potassium channels by genistein in rat cardiac ventricular myocytes. Cell Signal. 2004;16(3):333-41. doi:S0898656803001426.
9. Missan S, Linsdell P, McDonald TF. Tyrosine kinase and phosphatase regulation of slow delayed-rectifier K+ current in guineapig ventricular myocytes. J Physiol. 2006;573(Pt 2):469-82. doi: 10.1113/jphysiol.2005.104422.
10. Zhang DY, Wang Y, Lau CP, Tse HF, Li GR. Both EGFR kinase and Src-related tyrosine kinases regulate human ether-a-go-gorelated gene potassium channels. Cell Signal. 2008;20(10): 1815-21. doi:10.1016/j.cellsig.2008.06.006.
11. Cataldi M, Gaudino A, Lariccia V, Russo M, Amoroso S, di Renzo G, et al. Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism. J Pharmacol Exp Ther. 2004;309(1):208-15. doi:10.1124/jpet. 103.061184.
12. Qian JY, Guo L. Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicol In Vitro. 2010;24(3):960-72. doi:10.1016/j.tiv.2009.12.027.
13. Vianello F, Villanova F, Tisato V, Lymperi S, Ho KK, Gomes AR, et al. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinibinduced apoptosis via the CXCR4/CXCL12 axis. Haematologica. 2010;95(7):1081-9. doi:10.3324/haematol.2009.017178.
14. Arcangeli A. Expression and role of hERG channels in cancer cells. Novartis Found Symp. 2005;266:225-32 (discussion 32-4).
15. Li H, Du YM, Guo L, Jie S, Zhang S, Du W, et al. The role of hERG1 K+ channels and a functional link between hERG1 K+ channels and SDF-1 in acute leukemic cell migration. Exp Cell Res. 2009;315(13):2256-64. doi:10.1016/j.yexcr.2009.04.017.
16. Gong JH, Liu XJ, Shang BY, Chen SZ, Zhen YS. HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells. Oncol Rep. 2010;23(6):1747-56.
17. Crociani O, Guasti L, Balzi M, Becchetti A, Wanke E, Olivotto M, et al. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem. 2003;278(5): 2947-55. doi:10.1074/jbc.M210789200.
18. Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FW, et al. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem. 2002;277(21): 18528-34. doi:10.1074/jbc.M200592200.
19. Tamascar I, Ramanarayanan J. Targeted treatment of chronic myeloid leukemia: role of imatinib. Onco Targets Ther. 2009; 2:63-71.
20. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, et al. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110(4):1238-50. doi:10.1182/blood-2006-02-003772.
21. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer. 2005;93(7):781-92. doi: 10.1038/sj.bjc.6602775.
22. Legros L, Bourcier C, Jacquel A, Mahon FX, Cassuto JP, Auberger P, et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. Blood. 2004;104(2): 495-501. doi:10.1182/blood-2003-08-2695.
23. Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L, et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia. 2002;16(9):1791-8. doi:10.1038/sj.leu. 2402572.
24. Li H, Liu L, Guo L, Zhang J, Du W, Li X, et al. HERG K+ channel expression in CD34+/CD38-/CD123(high) cells and primary leukemia cells and analysis of its regulation in leukemia cells. Int J Hematol. 2008;87(4):387-92. doi:10.1007/s12185-008-0056-9.
25. Dolderer JH, Schuldes H, Bockhorn H, Altmannsberger M, Lambers C, von Zabern D, et al. HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol. 2010;36(1):72-7. doi:10.1016/j.ejso.2009.05.009.
26. Ding XW, Yang WB, Gao S, Wang W, Li Z, Hu WM, et al. Prognostic significance of hERG1 expression in gastric cancer. Dig Dis Sci. 2010;55(4):1004-10. doi:10.1007/s10620-009-0834-0.
27. Thomas D, Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des. 2006;12(18):2271-83.
28. Cui J, Melman Y, Palma E, Fishman GI, McDonald TV. Cyclic AMP regulates the HERG K(+) channel by dual pathways. Curr Biol. 2000;10(11):671-4. doi:S0960-9822(00)00516-9.
29. Bian JS, McDonald TV. Phosphatidylinositol 4, 5-bisphosphate interactions with the HERG K(+) channel. Pflugers Arch. 2007;455(1):105-13. doi:10.1007/s00424-007-0292-5.
30. Maier G, Palmada M, Rajamanickam J, Shumilina E, Bohmer C, Lang F. Upregulation of HERG channels by the serum and glucocorticoid inducible kinase isoform SGK3. Cell Physiol Biochem. 2006;18(4-5):177-86. doi:10.1159/000097666.
31. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002; 99(10):3792-800.
32. Korkolopoulou P, Viniou N, Kavantzas N, Patsouris E, Thymara I, Pavlopoulos PM, et al. Clinicopathologic correlations of bone marrow angiogenesis in chronicmyeloid leukemia: amorphometric study. Leukemia. 2003;17(1):89-97. doi:10.1038/sj.leu.2402769.
33. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99(6):2265-7.
34. Lin H, Xiao J, Luo X, Wang H, Gao H, Yang B, et al. Overexpression HERG K(+) channel gene mediates cell-growth signals on activation of oncoproteins SP1 and NF-kappaB and inactivation of tumor suppressor Nkx3.1. J Cell Physiol. 2007;212(1): 137-47. doi:10.1002/jcp.21015.